The UK High Court has ruled in favor of Alvotech SA in a legal dispute brought by Regeneron Pharmaceuticals and Bayer AG over the manufacture of AVT06, a biosimilar to Eylea (aflibercept). The court rejected a request for an injunction that would have blocked Alvotech's manufacturing activities in the UK. This decision allows Alvotech and its contract manufacturing organization to continue producing and stockpiling AVT06 ahead of the expiry of Eylea's Supplementary Protection Certificates on November 23, 2025. The ruling supports the planned commercial launch of AVT06 in the UK, the European Economic Area, and other countries following the certificate's expiry.
Disclaimer: This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Alvotech SA published the original content used to generate this news brief via EDGAR, the Electronic Data Gathering, Analysis, and Retrieval system operated by the U.S. Securities and Exchange Commission (Ref. ID: 0001171843-25-007238), on November 12, 2025, and is solely responsible for the information contained therein.